RECURSION PHARMACEUTICALS-A Share Price Today: Live Updates & Key Insights

RECURSION PHARMACEUTICALS-A share price today is $3.25, up -3.56%. The stock opened at $3.335 against the previous close of $3.37, with an intraday high of $3.415 and low of $3.215.

RECURSION PHARMACEUTICALS-A Share Price Chart

RECURSION PHARMACEUTICALS-A

us-stock
To Invest in {{usstockname}}
us-stock

RECURSION PHARMACEUTICALS-A Share Price Performance

$3.25 -0.0356(-3.56%) RXRX at 23 Mar 2026 03:06 PM Biotechnology
Lowest Today 3.215
Highest Today 3.415
Today’s Open 3.335
Prev. Close 3.37
52 Week High 7.18
52 Week Low 2.98
Day’s Range: Low 3.215 High 3.415
52-Week Range: Low 2.98 High 7.18
1 day return -
1 Week return -3.82
1 month return -4.25
3 month return -25.45
6 month return -34.37
1 year return -51.98
3 year return -53.08
5 year return -89.37
10 year return -

RECURSION PHARMACEUTICALS-A Institutional Holdings

Vanguard Group Inc 8.93

ARK Investment Management LLC 7.06

BlackRock Inc 6.01

Baillie Gifford & Co Limited. 4.50

ARK Innovation ETF 4.39

ARK Disruptive Innovation Full Composite 3.88

State Street Corp 3.46

Scottish Mortgage Ord 3.43

State Street® SPDR® S&P® Biotech ETF 3.07

Vanguard Total Stock Mkt Idx Inv 2.92

SoftBank Group Corp 2.78

Kinnevik AB (publ) 2.54

ARK Genomic Revolution ETF 2.38

ARK Genomic Revolution 2.21

Vanguard Small Cap Index 2.10

Geode Capital Management, LLC 2.07

MIC Capital Management UK LLP 1.83

iShares Russell 2000 ETF 1.75

NVIDIA Corp 1.46

Sumitomo Mitsui Trust Group Inc 1.41

Exor Investments (UK) LLP 1.39

Morgan Stanley - Brokerage Accounts 1.38

Amova Asset Management Americas, Inc 1.18

Vanguard Small Cap Growth Index Inv 1.17

Data Collective IV GP, LLC 1.12

NORGES BANK 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.06

Susquehanna International Group, LLP 0.83

Citadel Advisors Llc 0.80

UBS Asset Mgmt Americas Inc 0.79

Charles Schwab Investment Management Inc 0.76

Fidelity Small Cap Index 0.71

Baillie Gifford US Equity Growth 0.62

Vanguard US Growth Investor 0.62

iShares Russell 2000 Growth ETF 0.60

Amova ARK Disruptive Innovation A USD 0.60

iShares Biotechnology ETF 0.59

Fidelity Extended Market Index 0.52

Schwab US Small-Cap ETF™ 0.47

FT Nasdaq Artfcl Intllgnc and Rbtc ETF 0.44

RECURSION PHARMACEUTICALS-A Market Status

Strong Buy: 1

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

RECURSION PHARMACEUTICALS-A Fundamentals

Market Cap 1716.66 M

PB Ratio 1.525

PE Ratio 0.0

Enterprise Value 1059.25 M

Total Assets 1474.13 M

Volume 26878031

RECURSION PHARMACEUTICALS-A Company Financials

Annual Revenue FY25:74681000 74.7M, FY23:46928000 46.9M, FY22:39681000 39.7M, FY21:10000000 10.0M, FY20:3413000 3.4M

Annual Profit FY25:3728000 3.7M, FY23:3382000 3.4M, FY22:-8594000 -8.6M, FY21:10000000 10.0M, FY20:3413000 3.4M

Annual Net worth FY25:-644759000 -644.8M, FY23:-292562000 -292.6M, FY22:-239421000 -239.4M, FY21:-178074000 -178.1M, FY20:-87882000 -87.9M

Quarterly Revenue Q4/2025:35537000 35.5M, Q3/2025:5175000 5.2M, Q2/2025:19103000 19.1M, Q1/2025:14745000 14.7M, Q3/2024:26082000 26.1M

Quarterly Profit Q4/2025:36288000 36.3M, Q3/2025:-24418000 -24.4M, Q2/2025:-1058000 -1.1M, Q1/2025:-7084000 -7.1M, Q3/2024:14003000 14.0M

Quarterly Net worth Q4/2025:-108124000 -108.1M, Q3/2025:-162253000 -162.3M, Q2/2025:-171897000 -171.9M, Q1/2025:-202487000 -202.5M, Q3/2024:-95675000 -95.7M

About RECURSION PHARMACEUTICALS-A & investment objective

Company Information Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Organisation Biotechnology

Employees 600

Industry Biotechnology

CEO Dr. Najat Khan Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

RECURSION PHARMACEUTICALS-A FAQs

What is the share price of RECURSION PHARMACEUTICALS-A today?

The current share price of RECURSION PHARMACEUTICALS-A is $3.25.

Can I buy RECURSION PHARMACEUTICALS-A shares in India?

Yes, Indian investors can buy RECURSION PHARMACEUTICALS-A shares by opening an international trading and demat account with Motilal Oswal.

How to buy RECURSION PHARMACEUTICALS-A shares in India?

You can easily invest in RECURSION PHARMACEUTICALS-A shares from India by:

Can I buy fractional shares of RECURSION PHARMACEUTICALS-A?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of RECURSION PHARMACEUTICALS-A?

RECURSION PHARMACEUTICALS-A has a market cap of $1716.66 M.

In which sector does RECURSION PHARMACEUTICALS-A belong?

RECURSION PHARMACEUTICALS-A operates in the Biotechnology sector.

What documents are required to invest in RECURSION PHARMACEUTICALS-A stocks?

To invest, you typically need:

What is the PE and PB ratio of RECURSION PHARMACEUTICALS-A?

The PE ratio of RECURSION PHARMACEUTICALS-A is N/A and the PB ratio is 1.53.